WHO ICTRP trial
MYSTICS-RCT
JPRN-jRCTs051230077 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCTs051230077 |
|---|---|
| Public title | MYSTICS-RCT |
| Scientific title | Methotrexate as the second-line therapY for relapse or inadequate response to Steroid Therapy In patients with Cardiac Sarcoidosis: a multicenter Randomized Controlled Trial - MYSTICS-RCT |
| Primary sponsor | Izumi Chisato |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Conditions | cardiac sarcoidosis Cardiac sarcoidosis;Cardiac sarcoidosis |
| Interventions | We will randomly assign cardiac sarcoidosis patients diagnosed with steroid-resistant or relapsed cardiac sarcoidosis to a group receiving a combination of prednisolone and methotrexate, and a group receiving an increased dose of… |
| Registration date | Jul 25, 2023 |
| Target size | 120 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: